Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M907022199 on March 13, 2000
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/20/15563    most recent
M907022199v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marí, M.
Right arrow Articles by Cederbaum, A. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marí, M.
Right arrow Articles by Cederbaum, A. I.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 20, 15563-15571, May 19, 2000


CYP2E1 Overexpression in HepG2 Cells Induces Glutathione Synthesis by Transcriptional Activation of gamma -Glutamylcysteine Synthetase*

Montserrat Marí and Arthur I. CederbaumDagger

From the Department of Biochemistry and Molecular Biology, Mount Sinai School of Medicine, New York, New York 10029

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Induction of CYP2E1 (cytochrome P450 2E1) by ethanol appears to be one of the central pathways by which ethanol generates a state of oxidative stress. CYP2E1 is a loosely coupled enzyme; formation of reactive oxygen species occurs even in the absence of added substrate. GSH is critical for preserving the proper cellular redox balance and for its role as a cellular protectant. Since cells must maintain optimal GSH levels to cope with a variety of stresses, the goal of this study was to characterize the GSH homeostasis in human hepatocarcinoma cells (HepG2) that overexpress CYP2E1. This study was prompted by the finding that toxicity in CYP2E1-overexpressing cells was markedly enhanced after GSH depletion by buthionine sulfoximine treatment. CYP2E1-overexpressing cells showed a 40-50% increase in intracellular H2O2; a 30% increase in total GSH levels; a 50% increase in the GSH synthesis rate; and a 2-fold increase in gamma -glutamylcysteine synthetase heavy subunit (GCS-HS) mRNA, the rate-limiting enzyme in GSH synthesis. This GCS-HS mRNA increase was due to increased synthesis since nuclear run-on assays showed increased transcription in CYP2E1-expressing cells, and the GCS-HS mRNA decay after actinomycin D treatment was similar in CYP2E1-expressing cells and empty vector-transfected cells. The facts that treatment with GSH ethyl ester almost completely prevented the increase in GCS-HS mRNA and decreased H2O2 levels and that transient transfection with catalase (but not manganese-superoxide dismutase) produced a decrease in GCS-HS mRNA only in CYP2E1-expressing cells suggest a possible role for H2O2 in the induction of GCS-HS gene transcription. In contrast to results with HepG2 cells expressing CYP2E1, no increase in GCS-HS mRNA was found with a HepG2 cell line engineered to express human cytochrome P450 3A4. In summary, CYP2E1 overexpression in HepG2 cells up-regulates the levels of reduced GSH by transcriptional activation of GCS-HS; this may reflect an adaptive mechanism to remove CYP2E1-derived oxidants such as H2O2.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

GSH, the most abundant antioxidant in cells, plays a major role in the defense against oxidative stress-induced cell injury and is essential in maintenance of intracellular redox balance and the essential thiol status of proteins (1). In the liver, the cellular GSH level is determined by a balance between the rate of its synthesis and the rates of its utilization (conjugation) and loss (export) (2). Endogenous hydrogen peroxide (H2O2) is removed by GSH in the presence of glutathione peroxidase and can also be removed by catalase in the peroxisomes. Furthermore, conjugation with GSH, catalyzed by glutathione S-transferases (GST),1 is an integral step in the detoxification and elimination of diverse classes of toxic chemical compounds (3). Either glutathione peroxidase or GST can reduce organic hydroperoxides in the presence of GSH. Exposure of cells to a number of xenobiotic agents (4-8) and cytokines (9, 10) has been shown to result in an increase in the total intracellular GSH content. The first step in GSH biosynthesis is rate-limiting and is catalyzed by gamma -glutamylcysteine synthetase (GCS). The GCS holoenzyme is a heterodimer composed of a heavy (GCS-HS; Mr ~ 70,000) and a light (GCS-LS; Mr ~ 30,000) subunit (11), which are encoded by different genes located on chromosomes 1 and 6, respectively. Changes in GCS activity have been reported to result from regulation at the transcriptional (9-12) and/or post-transcriptional (13) level, and these changes may affect only the heavy or both the heavy and light subunits (13, 14). Most of the studies reported in the literature have examined transcriptional regulation of GCS-HS.

Induction of CYP2E1 (cytochrome P450 2E1) and formation of reactive oxygen species (ROS) and lipid peroxidation derivatives appear to be one of the mechanisms by which ethanol is hepatotoxic (15, 16). It has been demonstrated that CYP2E1, when reduced by NADPH-cytochrome P450 reductase, is a loosely coupled enzyme that displays high NADPH oxidase activity (17, 18). Formation of reactive oxygen species can occur even in the absence of added substrates, e.g. formation of superoxide and H2O2 by microsomes from CYP2E1-expressing cells was not altered by addition of substrates and ligands of CYP2E1 (19).

To directly demonstrate that ROS generated by CYP2E1 can promote hepatotoxicity even in the absence of substrate, a HepG2 cell line with enhanced expression of CYP2E1 was recently established (20). The CYP2E1-expressing cells (E47) have a slower growth rate than the empty vector-transfected control C34 cells when cellular GSH levels are maintained, but display a loss of cell viability when GSH synthesis is inhibited by treatment with BSO. However, we observed that despite increased production of ROS, GSH levels are not decreased in E47 cells compared with C34 cells. This suggested that a possible up-regulation of GSH synthesis and/or increased GSH turnover may occur in E47 cells in response to the increased oxidative stress. The goal of this study was to evaluate whether CYP2E1 overexpression could mediate an effect on GSH homeostasis.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

In Vitro Model and Cell Culture Conditions-- Two human hepatoma HepG2 sublines, which were established previously in our laboratory (20), were used as a model in this study. E47 and E43 cells contain the human CYP2E1 cDNA (kindly provided by Dr. F. J. Gonzalez, NCI, National Institutes of Health) inserted into the EcoRI restriction site of the pCI-neo expression vector (Promega, Madison, WI) in the sense orientation. C34 cells contain the pCI-neo vector alone. The HepG2 transduced clones C34 and E47 were cultured in minimal essential medium supplemented with 10% fetal calf serum, 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM glutamine in a humidified atmosphere in 5% CO2 at 37 °C. Cells were maintained in the presence of 0.5 mg/ml of Geneticin.

Most reagents were purchased from Sigma. The protein content of cell lysates was determined by the method of Lowry et al. (21) using the DC-20 protein assay kit (Bio-Rad), and 2',7'-dichlorofluorescein diacetate (DCFDA) was purchased from Molecular Probes, Inc. (Eugene, OR). Specific reagents are described below. CYP2E1 levels were routinely monitored by assaying the oxidation of p-nitrophenol to p-nitrocatechol.

GSH Assay-- Cells (1 × 106) were seeded onto 100-mm plates and incubated overnight before any treatment. Cells were washed twice with 1× PBS, detached by trypsinization, and treated with 10% (1:1, v/v) trichloroacetic acid to extract cellular GSH. The mixture was centrifuged at 13,000 × g for 1 min to remove denatured proteins, and GSH was determined by the enzymatic method of Tietze (22). The GSH content was assayed by following the increase in absorbance at 412 nm for 2 min in a cuvette containing 0.1 M sodium phosphate buffer (pH 7.5), 5 µM EDTA, 0.6 mM 5,5'-dithiobis(2-nitrobenzoic acid), 0.2 mM NADPH, 1 unit/ml glutathione reductase, and 10 µl of sample (corresponding to ~100 µg of protein) in a final volume of 1 ml. For determination of GSSG, the same 5,5'-dithiobis(2-nitrobenzoic acid) recycling assay was performed after using 2-vinylpyridine to remove reduced GSH (23). Briefly, 2 µl of 2-vinylpyridine and 6 µl of triethanolamine were simultaneously mixed with 100 µl of sample, followed by incubation in the dark at room temperature for 1 h before initiating the recycling assay. The kinetics of the reaction were monitored for 10 min. The increment in absorbance at 412 nm was converted to GSH concentration using a standard curve with known amounts of GSH.

DCF Fluorescence as a Measure of Hydrogen Peroxide Production-- Cells (1 × 106) were seeded onto 100-mm plates and incubated overnight before any treatment. DCFDA was added at a final concentration of 2 µg/ml, and plates were incubated for 30 min at 37 °C in the dark. Cells were washed twice with 1× PBS, trypsinized, and resuspended in 3 ml of 1× PBS; and fluorescence was immediately read in a Perkin-Elmer 650-10S fluorescence spectrometer at 490 nm for excitation and 525 nm for emission with a slit width of 5 nm for both excitation and emission monochromators. Background readings from cells incubated without DCFDA were substracted. Results are expressed as arbitrary units of fluorescence.

GSH Synthesis Rate Using Monochlorobimane-- Monochlorobimane can be used to measure activities of enzymes involved in GSH synthesis (24). Monochlorobimane forms a fluorescent adduct with GSH in a reaction catalyzed by GST. Cells were grown in 75-cm2 flasks to 80% confluence, washed twice with 1× PBS, scraped off in 0.01 M sodium phosphate plus 0.25 M sucrose (pH 7.4), sonicated for 3 s in a W220 sonicator (Ultrasonic, Farmingdale, NY), and centrifuged at 100,000 × g for 60 min. Cell extracts were dialyzed overnight at 4 °C to deplete the cytosolic GSH content in order to minimize feedback inhibition of GSH on GCS. The synthesis of GSH was followed at 37 °C in a cuvette containing a mixture of 100 mM Tris-HCl, 150 mM KCl, 20 mM MgCl2, 2 mM EDTA, 2 mM ATP, 10 mM glutamate, 10 mM glycine, and 0.4 mM cysteine plus 0.4 mM dithiothreitol and 100 µM monochlorobimane in a final volume of 2.5 ml at pH 7.3. The reaction was started by addition of cytosol (100 µl, 1-10 mg of protein) that was or was not preincubated with BSO (20 mM for 20 min) to specifically inhibit GCS activity, and formation of the GSH-bimane fluorescent complex was monitored over time at 37 °C using the Perkin-Elmer 650-10S fluorescence spectrometer with excitation at 385 nm and emission at 478 nm with a slit width of 5 nm for both excitation and emission monochromators. The difference in the rate of increase in fluorescence in the absence and presence of BSO is equivalent to the rate of GSH synthesis. The change in fluorescence was converted to GSH concentration using standard curves. Specifically, formation of fluorescent adduct was monitored by adding monochlorobimane (100 µM) and GST (0.1 unit/ml) to a cuvette containing GSH standards.

GSH Efflux-- To study GSH efflux, C34 and E47 cells were seeded onto 100-mm plastic dishes at 37 °C in a 5% CO2 and 95% air atmosphere and studied when confluency was almost reached. To measure GSH efflux, the cells were first incubated for 1 h with 0.5 mM acivicin to inhibit the enzyme gamma -glutamyl transpeptidase (25). The cells were then washed twice with Krebs-Henseleit buffer supplemented with 12.5 mM HEPES (pH 7.4) and incubated in 4 ml of Krebs buffer at 37 °C for 90 min. Aliquots of the supernatant (500 µl) were removed at 5, 30, 60, and 90 min, and GSH was determined as described above.

Enzyme Assays-- Glutathione peroxidase was assayed according to Flohé and Günzler (26) using t-BOOH as a substrate. The following solutions were added to a cuvette: 700 µl of solution containing 50 mM Tris-HCl plus 5 mM EDTA (pH 7.4), 1.6 mM GSH, 0.32 mM NADPH, and 0.8 units/ml glutathione reductase; 70 µl of sample (~0.3-1.0 mg of protein); and 350 µl of 0.007% (v/v) t-BOOH. The decrease in absorbance at 340 nm was followed for 4 min. Results are expressed as units of specific activity defined as the amount of enzyme that consumes 1 µmol of NADPH/min/mg of protein. GST activity was determined according to the method of Habig et al. (27) with some modifications. The reaction was carried out in 0.1 M potassium phosphate (pH 6.5), 1 mM GSH, and 1 mM 1-chloro-2,4-dinitrobenzene in the presence of 50 µl of cell lysate (~0.3-1.0 mg of protein), and the increase in absorbance was monitored at 340 nm and 25 °C over a 4-min time period. Results are expressed as units of specific activity defined as the amount of the enzyme that produces 1 µmol of conjugated product/min/mg of protein. Glutathione reductase was determined according to the method of Carlberg and Mannervick (28). The following solutions were added sequentially to a cuvette: 800 µl of 0.125 M potassium phosphate plus 1.25 mM EDTA (pH 7.0), 50 µl of 2 mM NADPH, 50 µl of 20 mM GSSG, and 100 µl of sample (~0.1-0.3 mg of protein); and the decrease in absorbance was monitored at 340 nm for 2 min. One unit of glutathione reductase is defined as the amount of enzyme that catalyzes the oxidation of 1 µmol of NADPH/min/mg of protein. Total superoxide dismutase activity was measured according to Paoletti and Mocali (29). One unit of superoxide dismutase activity is defined as the amount of cell extract required to inhibit the rate of NADPH oxidation of the control by 50%. The control consisted of a sample in which the cell extract was omitted from the reaction mixture. The following solutions were sequentially added to a cuvette: 0.8 ml of 100 mM triethanolamine/diethanolamine (pH 7.4), 40 µl of 7.5 mM NADPH, 25 µl of 100 mM EDTA plus 50 mM MnCl2, and 100 µl of dialyzed cell extract (~0.5 mg of protein) or buffer. The contents were mixed, and the absorbance was read at 340 nm against air until a stable base line was observed as recorded over a 5-min period. Then, 100 µl of 10 mM beta -mercaptoethanol was added, followed by mixing; and the decrease in absorbance at 340 nm was monitored for over a 20-min reaction period. Measurements of the relative rates for both the control and cell extract were made from the linear portion of the curves.

Northern Blotting-- Total RNA was isolated using the Trizol reagent (Life Technologies, Inc.). Ten micrograms of RNA was electrophoresed under denaturing conditions on formaldehyde-containing 0.9% agarose gels and transferred onto GeneScreen nylon membranes (NEN Life Science Products). RNA was UV-cross-linked at 1200 J × 100 for 30 s and prehybridized in a hybridization oven for 2 h at 42 °C in 5× SSC, 50% formamide, 50 mM potassium phosphate (pH 6.5), and 1× Denhardt's solution containing 0.1 mg/ml denatured salmon sperm DNA. cDNA probes were radiolabeled with [alpha -32P]dCTP (specific activity > 3000 Ci/mmol; Amersham Pharmacia Biotech) using a random primer DNA labeling kit (Amersham Pharmacia Biotech). Immobilized RNA was hybridized in 0.1% SDS, 5× SSC, 50% formamide, 50 mM potassium phosphate (pH 6.5), 1× Denhardt's solution, and 12.5× dextran sulfate with 106 cpm/ml labeled cDNA and 0.1 mg/ml denatured salmon sperm DNA for 16 h at 42 °C. Blots were washed four times for 15 min with 2× SSC and 0.5% SDS at 65 °C, exposed to a phosphor storage screen for a fixed period of time according to the hybridized cDNA, and scanned in a PhosphorImager (Molecular Dynamics, Inc., Sunnyvale, CA). Values were normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA using ImageQuant software. The GCS-HS cDNA was obtained from American Type Culture Collection (ATCC 1064067, Manassas, VA). The GCS-LS probe was obtained by reverse transcription-polymerase chain reaction amplification of a fragment of 513 base pairs with the primers 5'-GGA GTT TCC AGA TGT CTT GG-3' and 5'-GGA ATG CTT TCC TGA AGA GC-3'; the complete GCS-LS cDNA sequence was obtained from a published sequence (GenBankTM/EBI accession L35546) (30).

Nuclear in Vitro Run-on Transcription Assays-- Cultured cells were washed twice with sterile 1× PBS, scraped off, and transferred into 15-ml Falcon tubes for centrifugation at 500 × g at 4 °C for 5 min. Pellets were loosened and resuspended in 4 ml of Buffer A (10 mM Tris (pH 7.4), 10 mM NaCl, and 3 mM MgCl2). After addition of 0.5% (v/v) Nonidet P-40, samples were vortexed for 10 s and kept on ice for 10 min. After a second centrifugation, supernatants containing cytoplasmic RNA were discarded, and 4 ml of Buffer A was added. Samples were kept on ice for 10 min and spun down. Nuclei were collected in 100 µl of storage buffer (50 mM Tris (pH 8.3), 40% glycerol, 5 mM MgCl2, and 0.1 mM EDTA) and immediately stored at -70 °C until analyzed.

Transcription was assayed in vitro with 100 µl of nuclei (isolated from ~25 × 106 cells), 100 µCi of [32P]UTP, and 100 µl of assay buffer (2.5 mM MnCl2, 125 mM Tris (pH 7.4), 12.5 mM MgCl2, 2.5 mM dithiothreitol, 2.5 mM ATP, 1.25 mM GTP, 1.25 mM CTP, and 375 mM KCl). The reaction was carried out at 25 °C for 45 min and stopped by adding DNase I (RNase-free) at a final concentration of 20 µg/ml. After incubation at 30 °C for 5 min, RNA was released from the nuclei by treatment with 1% SDS, 5 mM EDTA, 10 mM HEPES (pH 7.5), and 200 µg/ml proteinase K at 42 °C for 30 min. Newly transcribed RNA was isolated using the Trizol reagent.

Eight micrograms of each cDNA of interest was denatured in 0.25 N NaOH and 0.5 M NaCl for 10 min at room temperature and diluted in 0.1× SSC and 0.125 N NaOH. Samples were blotted onto GeneScreen membranes, neutralized in 0.5 N NaCl and 0.5 M Tris (pH 7.5), and UV-cross-linked. Prehybridization was carried out for 6 h at 42 °C, and purified denatured riboprobes (1 × 106 cpm/ml) were used for hybridization for 72 h at 42 °C. The composition of the hybridization buffer was the same as described for the Northern blot assay, using 0.1 mg/ml bakers' yeast tRNA instead of the salmon sperm DNA. After four washes of 15 min each with 2× SSC and 0.5% SDS at 65 °C, membranes were exposed to the phosphor storage screen, and the signals were quantified using the GAPDH mRNA signal as a control.

Transient Transfection Experiments-- Transient transfection experiments were carried out with pCI vector containing CYP2E1 in the antisense (pCI-AS-2E1) or sense (pCI-2E1) orientation, pcDNA3-MnSOD (kindly provided by Dr. Larry Oberley, University of Iowa, Iowa City, IA), or pZeoSV2-catalase (kindly provided by Dr. A. Melendez, Albany Medical College, Albany, NY). Controls for these experiments included transfections with the empty vectors pCI, pZeoSV2, and pcDNA3. Transfection of C34 and E47 cells was carried out with 10 µg of the appropriate plasmid, 3 µg of pL7-Lac (kindly provided by Dr. Robert Krauss, Mount Sinai School of Medicine, New York, NY), and 30 µl of Fugene 6 (Roche Molecular Biochemicals). After 48 h, the efficiency of the transfection was determined by X-gal staining; and at 48 and 96 h, total RNA was isolated to study GCS-HS and GAPDH mRNA expression by Northern blotting.

Statistics-- Results refer to means ± S.D. and are average values from three to six values per experiment; experiments were repeated at least twice. Statistical evaluation among groups was carried out using Student's t test, and p < 0.05 was considered significant.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

GSH Levels and Intracellular H2O2 Production-- GSH is among the most important intracellular antioxidants. Since ROS generated from CYP2E1 or other sources can be removed either by direct reaction with GSH (e.g. the hydroxyl radical) or by the glutathione peroxidase reaction (e.g. H2O2), we investigated the effect of CYP2E1 overexpression on the regulation of total cellular GSH equivalents (GSH + GSSG) and the generation of hydrogen peroxide as an indicator of ROS. Hydrogen peroxide was monitored by quantification of fluorescence of DCF, a highly fluorescent probe sensitive to peroxides. BSO is an effective inhibitor of gamma -glutamylcysteine synthetase, the rate-limiting enzyme for GSH synthesis. The intracellular GSH levels in E47 and C34 cells with or without BSO treatment were evaluated (Fig. 1). In the absence of BSO treatment, E47 cells cultured in normal minimal essential medium had a significant 30% increase in total GSH compared with C34 cells (Fig. 1A); GSSG levels were very low and similar in both cell lines (data not shown). As expected, BSO treatment caused a decline in intracellular GSH in both cell lines; although the fall in intracellular GSH in E47 cells was linear over the 8-h reaction period, the decline in GSH in C34 cells showed a lag of ~4 h. Thereafter, the fall in GSH was similar for E47 and C34 cells (Fig. 1B). To determine if the decline in GSH levels was due, at least in part, to GSH efflux from the cells, the GSH content in the medium was assayed. GSH efflux could not be observed unless acivicin, an inhibitor of gamma -glutamyl transpeptidase was added, confirming reports of others (25). The initial levels of GSH in the medium of E47 cells were ~25% higher than the levels in the medium of C34 cells, most likely a reflection of the 30% higher intracellular GSH levels in E47 cells. The rate of GSH efflux, as assayed over a 90-min time period (Fig. 1C), was 36.0 ± 4.0 pmol/min/mg of protein in C34 cells, whereas the rate in E47 cells was 50.3 ± 3.5 pmol/min/mg of protein (~40% higher). From the rate of GSH efflux, ~6 nmol of GSH/mg of protein would be released from E47 cells in 2 h, which is equivalent to the loss of intracellular GSH in 2 h (Fig. 1B). Thus, most of the decline in intracellular GSH in E47 cells, after BSO treatment to prevent new synthesis, is due to GSH efflux from the cells. Similar calculations with C34 cells indicated that ~4 nmol of GSH/mg of protein would be excreted from the cells in 2 h, which is greater than the 1-nmol decline in intracellular GSH found at 2 h. The reasons for this discrepancy and the lag in the fall in GSH in C34 cells are not known.


View larger version (17K):
[in this window]
[in a new window]
  		Fig. 1.   Intracellular GSH levels in C34 and E47 cells (A), time course for the effect of BSO on GSH levels (B), and GSH efflux (C). A, steady-state GSH levels were determined as described under "Materials and Methods." B, C34 and E47 cells were treated with 0.1 mM BSO for the times indicated. Thereafter, the medium was removed, and cells were trypsinized and treated with 10% trichloroacetic acid. GSH was determined, and the results are expressed as nmol of GSH consumed after BSO treatment. C, GSH efflux was measured after inhibition of gamma -glutamyl transpeptidase by acivicin pretreatment (0.5 mM for 1 h). The results are expressed as means ± S.D. (n = 6). *, p < 0.05 versus C34 cells. prot, protein.

As shown in Fig. 2, E47 cells labeled with DCFDA displayed a significant 40-50% increase in DCF fluorescence compared with C34 cells; this fluorescence was further elevated after treatment with BSO for 24-48 h, indicating the critical role of GSH in detoxification of ROS generated by CYP2E1 in E47 cells. It is interesting that increased DCF fluorescence was observed in E47 cells even though GSH levels were elevated in these cells. The small increase in DCF fluorescence in C34 cells 24-48 h after BSO treatment likely reflects the effectiveness of the residual GSH (~20% of control values) in maintaining antioxidant function coupled with the lack of a significant oxidative stress in these cells as compared with E47 cells (20). Indeed, C34 cells remained fully viable after BSO treatment, in contrast to the loss of viability of E47 cells.


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 2.   DCF fluorescence in C34 and E47 cells. Untreated C34 and E47 cells or cells treated with 0.1 mM BSO for 24 and 48 h were evaluated for production of ROS. After the incubation period, 2 µg/ml DCFDA was added to each plate for 30 min. Cells were washed twice with PBS and trypsinized, and DCF fluorescence was determined as described under "Materials and Methods." The results are expressed as means ± S.D. (n = 6). *, p < 0.05 versus C34 cells. A.U/mg prot, arbitrary units/mg of protein.

Antioxidant Enzyme Activities-- To maintain the intracellular GSH levels, GSSG is reduced back to GSH by glutathione reductase at the expense of NADPH, or de novo synthesis of GSH occurs. Organic hydroperoxides can be reduced by either glutathione peroxidase or GST. Superoxide is converted to H2O2 by superoxide dismutase. H2O2 can be removed either by reduction by GSH in the cytosol as catalyzed by glutathione peroxidase or by catalase in the peroxisomes. As shown in Table I, there was no difference in the activities of glutathione reductase and superoxide dismutase in C34 and E47 cells. There was a 30% decrease in glutathione peroxidase activity in cells overexpressing CYP2E1. However, there was a 2-fold increase in GST activity in E47 cells compared with C34 cells. Thus, there appears to be a mixed response by enzymes involved in GSH homeostasis to the presence of CYP2E1 in E47 cells, with increases (GST), decreases (glutathione peroxidase), or no change (glutathione reductase) being observed.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Antioxidant enzyme activities in C34 and E47 cells
The activities of glutathione reductase, superoxide dismutase, glutathione peroxidase, and GST were determined as described under "Materials and Methods." Results are expressed in milliunits/mg of cell protein for glutathione reductase, glutathione peroxidase, and GST and in units/mg of cell protein for superoxide dismutase and refer to means ± S.D. (n = 6).

Effect of CYP2E1 on GCS-HS mRNA Expression-- In view of these results, we investigated possible mechanisms that could account for the up-regulation of GSH levels in E47 cells. The first step of GSH biosynthesis is rate-limiting and catalyzed by GCS. GCS is composed of a heavy (GCS-HS; Mr ~ 73,000) and a light (GCS-LS; Mr ~ 30,000) subunit, which are encoded by different genes. The heavy subunit exhibits all the catalytic activity as well as feedback inhibition by GSH. The light subunit alone is inactive, but allows the holoenzyme to be catalytically more efficient and less subject to inhibition by GSH than the heavy subunit alone. Northern blots of GCS-HS and GAPDH (used as a loading control) mRNA levels are shown in Fig. 3A. Control cells (C34) expressed two transcripts of GCS-HS mRNA with sizes of 4.1 and 3.2 kilobases. CYP2E1-expressing cells (E47) showed a 2-fold increase in these two transcripts of GCS-HS mRNA. E43 cells, a HepG2 cell line that was developed at the same time as E47 cells and that expresses similar levels of CYP2E1, also showed a 2-fold induction of GCS-HS mRNA (Fig. 3B). The ratio of GCS-HS to GAPDH mRNA was assigned an arbitrary value of 1 in C34 cells. This ratio was increased ~2-fold in E47 and E43 cells. Northern blotting for GCS-LS was also carried out (Fig. 3C). A 1.4-kilobase transcript was detected in C34 cells, and there was a 2-fold increase in this transcript in E47 cells. Thus, there appears to be coordinate regulation of the mRNAs for both subunits of GCS in E47 cells.


View larger version (44K):
[in this window]
[in a new window]
  		Fig. 3.   Representative Northern blots of GCS mRNA. A, Northern blot of GCS-HS in C34 and E47 cells; B, Northern blot of GCS-HS in C34, E47, and E43 cells; C, Northern blot of GCS-LS in C34 and E47 cells. The same blots were sequentially probed with cDNA for GCS-HS (A and B) or GCS-LS (C) and GAPDH. Quantification of Northern blots was performed as relative mRNA signal (GCS-HS or GCS-LS) corrected for differences in loading using the GAPDH signal. The ratio of GCS-HS or GCS-LS to GAPDH in C34 cells was assigned a value of 1. The results are expressed as means ± S.D. (n = 3). *, p < 0.05 versus C34 cells. kb, kilobases.

An increase in GCS-HS mRNA may reflect either an increased transcription rate of the GCS-HS gene or a stabilization of the mRNA. The half-life of GCS-HS mRNA in C34 and E47 cells was assessed in the presence of actinomycin D (10 µg/ml). As shown in Fig. 4, the half-life in C34 and E47 cells was similar (~4 h), indicating that post-transcriptional modification of GCS-HS mRNA cannot account for the increase in GCS-HS mRNA in CYP2E1-overexpressing cells. To demonstrate increased transcription of the GCS-HS gene, nuclear run-on experiments were carried out. Indeed, the nuclear run-on revealed an increased capacity of E47 cells to transcribe the GCS-HS gene (Fig. 5). The ratio of newly synthesized GCS-HS to GAPDH mRNA was elevated from a value of 1 in C34 cells to a value of 1.7 in E47 cells. This increase in transcription under steady-state conditions is similar to the increase in mRNA levels as detected by Northern blotting.


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 4.   Stability of GCS-HS mRNA in E47 and C34 cells. To inhibit mRNA synthesis, C34 and E47 cells were incubated in the presence of 10 µg/ml actinomycin D for 0-8 h. At the indicated times, total RNA was extracted for Northern blot analysis. The half-life of GCS-HS mRNA in C34 and E47 cells was ~4 h. Data represent one of three experiments.


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 5.   Transcriptional regulation of the GCS-HS gene. Intact nuclei of C34 and E47 cells were isolated, and the in vitro transcription of the GCS-HS gene relative to GAPDH was determined as described under "Materials and Methods." Data represent one of two different sets of experiments.

GSH Synthesis Rate-- To determine if the increase in GCS-HS mRNA was correlated with a higher enzyme activity, we determined the de novo capacity to synthesize GSH. Cytosolic fractions from CYP2E1-overexpressing cells showed a 50% increase in the rate of GSH synthesis as detected using monochlorobimane as a probe; the rate of GSH synthesis in C34 cells was 0.235 ± 0.05 nmol of GSH/min/mg of protein, whereas the rate in E47 cells was 0.360 ± 0.04 (n = 3; p < 0.05).

Effect of Glutathione Ethyl Ester-- To further characterize the nature of CYP2E1-induced transcriptional activation of GCS-HS mRNA, GSH, which may act as an antioxidant or feedback regulator of GSH synthesis, was added to the culture medium, and the effect on the GCS-HS mRNA levels was determined. Glutathione ethyl ester (GSH-EE) has been reported to be effectively transported into human cells and converted intracellularly to GSH (31) and therefore was used as the source of added GSH. As shown in Fig. 6A, GSH-EE increased the content of GSH in C34 cells by 50%, but produced only a 14% increase in the already elevated GSH levels in E47 cells; in fact, GSH-EE equalized the GSH content in the two cell lines. Importantly, GSH-EE lowered DCF fluorescence in E47 cells to the level found in C34 cells (Fig. 6B). The quenching of ROS as reflected by the decreased DCF fluorescence by added GSH-EE may account for the lack of a significant enhancement of intracellular GSH levels in E47 cells by added GSH-EE. GSH-EE had no effect on GCS-HS mRNA levels in C34 cells, but largely prevented the increase in this mRNA found in E47 cells (Fig. 6C), consistent with the decrease in DCF fluorescence that GSH-EE produced in these cells. Because GSH-EE generates ethanol, controls were treated with an equimolar (2.5 mM) dose of ethanol. This dose of ethanol did not produce any effect on the parameters measured.


View larger version (38K):
[in this window]
[in a new window]
  		Fig. 6.   Effect of GSH-EE on C34 and E47 cells. C34 and E47 cells were treated with 2.5 mM GSH-EE. After 24 h of incubation, glutathione content (A), DCF fluorescence (B), and GCS-HS mRNA (C) were determined as described under "Materials and Methods." Quantification of Northern blots was performed as relative GCS-HS mRNA signal corrected for differences in loading using the GAPDH signal. The ratio of GCS-HS to GAPDH in C34 cells was assigned a value of 1. The results are expressed as means ± S.D. of three cell preparations. *, p < 0.05 versus C34 cells.

Transfection with Catalase Decreases GCS-HS mRNA Expression in E47 Cells-- Several antioxidants, primarily preventive against lipid peroxidation, such as trolox, vitamin E, vitamin C, uric acid, and the iron chelator desferrioxamine, did not lower the elevated GCS-HS mRNA levels in E47 cells (data not shown). The effectiveness of GSH-EE suggested the possibility that H2O2 may be a critical ROS important in the increase in GCS-HS mRNA found in E47 cells. We therefore transiently transfected C34 and E47 cells with catalase and, as an additional control, besides empty vector, with manganese-superoxide dismutase. Plasmids pcDNA3-MnSOD and pZeoSV2-catalase and control plasmids pZeoSV2 and pcDNA3 were used for transient transfection (Fig. 7A). Transfection with catalase produced an ~30% decrease in the GCS-HS mRNA content in CYP2E1-expressing cells. Manganese-superoxide dismutase had no effect on the levels of GCS-HS mRNA (data not shown). There was no effect of catalase (Fig. 7A) or manganese-superoxide dismutase on the GCS-HS mRNA levels in C34 cells. The efficiency of the transfections, assessed by X-gal staining, was 25% in both cell lines.


View larger version (59K):
[in this window]
[in a new window]
  		Fig. 7.   Effect of transfection with catalase or sense and antisense CYP2E1 in C34 and E47 cells. C34 and E47 cells were transfected with catalase (A) or sense and antisense CYP2E1 (B), and total RNA was isolated after 96 h. Northern blotting for GCS-HS and GAPDH was performed. Quantification of Northern blots, discussed under "Results," was performed as relative GCS-HS mRNA signal corrected for differences in loading using the GAPDH signal. The ratio of GCS-HS to GAPDH in C34 cells was assigned a value of 1.

Role of CYP2E1 in the Induction of GCS-HS mRNA-- The only apparent difference between E47 and C34 cells is the presence of CYP2E1. It appears that the induction of GCS-HS mRNA in E47 cells is caused by the expression of CYP2E1 in these cells. To validate this idea, we transiently transfected plasmids pCI, pCI-AS-2E1, and pCI-2E1 into E47 and C34 cells (Fig. 7B). The presence of CYP2E1 in C34 cells, after transfection with pCI-2E1, caused a 20% increase in GCS-HS mRNA. pCI-AS-2E1 had no effect, consistent with the absence of CYP2E1 in C34 cells. In E47 cells, transfection with pCI-AS-2E1 decreased the levels of GCS-HS mRNA ~10%; however, there was a 30% increase in GCS-HS mRNA in cells transiently transfected with pCI-2E1. The efficiency of transfection was between 20 and 30% for all plasmids used with both cell lines.

Comparison between CYP2E1 and CYP3A4 in Mediating GCS-HS mRNA Induction-- The control C34 cells, like the parental cell line, do not contain or express very low levels of P450 isoforms. To ascertain if induction of the GCS-HS gene in E47 cells could be due to the overexpression of any P450, we evaluated the ability of CYP3A4 (cytochrome P450 3A4) to increase GCS-HS mRNA levels. A HepG2 cell line that constitutively and stably expresses CYP3A4 has recently been developed by methods similar to those used for establishing E47 cells.2 The CYP3A4-overexpressing HepG2 cells contain the human CYP3A4 cDNA (kindly provided by Dr. F. J. Gonzalez) inserted into the EcoRI site of the pCI-neo expression vector. Successful expression of CYP3A4 in these cells was demonstrated by Northern and Western blot analyses and by oxidation of a typical CYP3A4 substrate, fentanyl.2 The content of CYP3A4 in these cells, ~40 pmol/mg of microsomal protein, was similar to the content of CYP2E1 in E47 cells. In two independent experiments of DCF fluorescence as detected by flow cytometry, ROS production with the CYP3A4-expressing cells was 22% greater than that found with the control C34 cells. By contrast, DCF fluorescence with E47 cells was 145% greater than that with control cells. A comparison of GCS-HS mRNA levels in C34, E47, and CYP3A4-expressing cells was made. As shown in Fig. 8, CYP3A4-expressing cells showed no increase in GCS-HS mRNA as compared with empty vector-transfected cells (C34). This result suggests that there may be some selectivity in the induction of the GCS-HS gene by the CYP2E1-expressing cells, at least as compared with one other P450 isoform. It is interesting to speculate that the lack of increase in GCS-HS mRNA in the CYP3A4-expressing cells, in contrast to the increase found in E47 cells, may reflect the similar rates of production of ROS, as detected by DCF fluorescence, in the CYP3A4-expressing cells and C34 cells.


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 8.   Comparison of induction of GCS-HS mRNA in HepG2 cells. Northern blotting of GCS-HS and GAPDH was performed with RNA isolated from C34, E47, and CYP3A4-expressing cells. Quantification of Northern blots was performed as relative GCS-HS mRNA signal corrected for differences in loading using the GAPDH signal. The ratio of GCS-HS to GAPDH in C34 cells was assigned a value of 1.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

As summarized in a recent publication (32), the effects of chronic ethanol treatment on hepatic levels of GSH are not clear, with reports of decreased GSH levels (33, 34), unchanged levels (35), or even increased levels (36). A more consistent finding is that chronic ethanol treatment lowers mitochondrial GSH levels, due to defects in mitochondrial GSH transport (37). A recent study using the intragastric infusion model of ethanol administration reported that liver GSH levels declined by 40%, although GCS activity and GCS-HS mRNA levels increased 2-fold (32). The decline in GSH despite the induction of GCS was suggested to reflect other factors, including dietary, e.g. cysteine availability, important in determining the steady-state GSH levels. The above study (32) is the first report that chronic ethanol ingestion increased GCS-HS expression and activity. Among several biochemical alterations that occur in the intragastric infusion model are development of oxidative stress and striking increases in the content of CYP2E1. Whether CYP2E1 and oxidative stress play a role in the induction of GCS in this model remains to be determined. This led to the current investigation on the effect of CYP2E1 on glutathione homeostasis and possible induction of GCS activity and expression. An additional reason for the current study was that previous results showed that GSH appears to be essential in protecting HepG2 cells against CYP2E1-derived oxidative stress since BSO treatment, which depletes cellular GSH, resulted in a striking loss of viability of E47 cells, without any effect on the control C34 cells (20). E47 cells grow at a slower rate than the control C34 cells, yet despite this slow growth rate, E47 cells are fully viable as long as GSH levels are maintained. This suggested a possible up-regulation of GSH synthesis and/or increased turnover (20).

In the current study, an increase in GSH levels and in ROS production in CYP2E1-expressing HepG2 cells was observed. The results with DCFDA as a fluorogenic probe provide evidence for an increase in production of ROS in E47 cells, and the further increase after BSO treatment confirms the major role of GSH detoxification of ROS especially in CYP2E1-expressing cells. Although studies with isolated microsomes or reconstituted systems have demonstrated an increased ability of CYP2E1 to produce ROS (17-19), the current results extend this capability to intact cells. To our surprise, GSH levels were higher in E47 cells, even in the presence of increased production of ROS. This suggested the possibility that GSH synthesis might be elevated perhaps as an adaptive response by E47 cells to a state of oxidative stress. GSH efflux from E47 cells was also higher than that from C34 cells, consistent with an up-regulation of GSH synthesis. These observations led to subsequent studies to determine why GSH levels are elevated in E47 cells.

Because all eukaryotic cells maintain high concentrations of GSH or its analogs (38), the maintenance of intracellular GSH levels is indispensable for normal cell function and survival. The ability to maintain cellular functions under conditions of oxidative stress depends on the rapid induction of protective antioxidant systems. GSH synthesis and GCS-HS mRNA transcription have been shown to be increased as an adaptive mechanism against different kinds of insults leading to oxidative stress (6) such as exposure to tumor necrosis factor (9), nitric oxide (10), 4-hydroxy-2-nonenal (13), beta -naphthoflavone (7), and okadaic acid and menadione (39). The increase in GSH levels in E47 cells is due to an increase in de novo synthesis of GSH since this increase correlates with a 50% increase in GCS activity, the rate-limiting enzyme involved in GSH synthesis. The GCS-HS mRNA is increased 2-fold in cells overexpressing CYP2E1. Run-on transcription assays and mRNA stabilization assays were performed to show that this increase in GCS-HS mRNA was due to an increase in transcription. A 2-fold increase in GCS-LS mRNA is also observed in E47 cells, suggesting the possibility of coordinate induction of the two genes encoding the two subunits of GCS. These results suggest that CYP2E1 up-regulates the levels of reduced GSH by transcriptional activation of GCS genes, perhaps as an adaptive mechanism for removal of CYP2E1-derived ROS such as H2O2. To our knowledge, this appears to be the first report of a gene up-regulated by CYP2E1 (or CYP2E1-derived ROS; discussed below).

Increased levels of GSH can protect cells against oxidative stress by directly acting as an antioxidant or by serving as a substrate for removal of ROS or reactive metabolites by antioxidant enzymes. In this respect, it is interesting that the activity of GST was found to be increased in E47 cells. Preliminary experiments have shown that the elevated GST activity is associated with increased mRNA levels for the A1 and A2 Alpha GST isoforms; the Alpha GST isoforms are the major GST present in HepG2 cells (40). Thus, Alpha GST may be another gene up-regulated by CYP2E1. Recent experiments have confirmed the importance of human Alpha GST isoforms such as A1 and A2 in protecting cells against oxidative stress (41). There appears to be some selectivity in E47 cells for increasing the activity of enzymes important for GSH homeostasis, e.g. GST and GCS, as glutathione reductase activity is not altered, whereas glutathione peroxidase activity is decreased. The last is known to be sensitive to oxidative stress (42).

Since the cloning of the promoter of GCS-HS mRNA (43), different transcription factors have been implicated in the transcriptional regulation of the GCS-HS gene. Recent studies by Morales et al. (9) and Sekhar et al. (5) have confirmed the importance of AP-1 activity in mediating the effect of oxidative stress on GCS-HS transcription. On the other hand, Mulcahy et al. (7) described a distal antioxidant response element (ARE-4) that mediates beta -naphthoflavone-inducible expression of GCS-HS. In E47 cells, AP-1 (activator protein-1), ARE-4, NF-kappa B, and SP-1 do not appear to be involved in the increased transcription of the GCS-HS gene, as in preliminary electrophoretic mobility gel shift assays using consensus sequences for NF-kappa B (5'-AG TGA GGG GAC TTT CCC AGG C-3'), AP-1 (5'-CGC TTG ATG ACT CAG CCG AA-3'), and SP-1 (5'-ATT CGA TCG GGG CGG GGC GAG C-3') or the specific ARE-4 sequence from the human GCS-HS 5'-flanking region (5'-GCA CAA AGC GCT GAG TCA CGG G-3') and nuclear extracts from E47 and C34 cells, we could not detect enhanced binding of these factors to the appropriate oligonucleotides (data not shown). Different mechanisms and cis-acting elements may be involved in mediating CYP2E1-dependent transcriptional changes of the GCS-HS gene in these cells. Further studies including use of recorder constructs containing various elements of the promoter region of the GCS-HS gene and of oxidant-sensitive transcription factors are planned to determine why the GCS-HS gene is up-regulated in E47 cells.

To further evaluate the nature of CYP2E1 induction of the GCS-HS gene, the effect of antioxidants was studied. Lipid peroxidation reactions do not appear to play an important role in explaining the up-regulation of the GCS-HS gene since addition of classical inhibitors of lipid peroxidation does not prevent the increase in GSH content or GCS-HS mRNA. These agents were previously shown to prevent the toxicity by arachidonic acid or ferric nitrilotriacetate to E47 cells, demonstrating their effectiveness as antioxidants and inhibitors of lipid peroxidation (44, 45). GSH-EE was effective in preventing the increase in GCS-HS mRNA in E47 cells. This action of GSH-EE appears to be due to detoxification of ROS as detected by decreased DCF fluorescence and not to feedback inhibition by elevated cellular levels of GSH because GSH-EE did not decrease the level of GCS-HS mRNA in C34 cells, although GSH levels were raised to the same value as in E47 cells. In E47 cells, GSH-EE did lower the DCF fluorescence to levels found in C34 cells; and under these conditions of lowered ROS levels, GCS-HS mRNA levels also decreased. These findings indicate that GSH is crucial in combating the oxidative stress derived from CYP2E1 overexpression.

As a second approach, transfection with plasmids containing the antioxidant enzyme catalase or manganese-superoxide dismutase was performed. Transfection with catalase resulted in a 30% decrease in GCS-HS mRNA levels in CYP2E1-expressing cells, whereas there was no effect in control cells. This suggests that H2O2 plays an important role in CYP2E1-mediated induction of GCS, which is consistent with the enhanced DCF fluorescence and the effect of GSH-EE in E47 cells. Transfection with manganese-superoxide dismutase did not cause any change in the GCS-HS mRNA levels in E47 or C34 cells.

To provide further evidence for a direct role of CYP2E1 in the transcriptional activation of GCS-HS, transient transfection experiments were performed with vectors containing CYP2E1 in the sense (pCI-2E1) and antisense (pCI-AS-2E1) orientations and control pCI plasmid. In the pCI-2E1-transfected cells, there was a further 30% increase in the GCS-HS mRNA level in the CYP2E1-expressing cells (E47) and a 20% increase in the control cells (C34). Transfection with the plasmid pCI-AS-2E1 had no effect in C34 cells, but produced a slight decrease in GCS-HS mRNA in E47 cells. These findings show an association between levels of CYP2E1 expression and GCS-HS induction, as the levels of GCS-HS mRNA followed this order: E47 plus pCI-2E1 > E47 > E47 plus pCI-AS-2E1 > C34 plus pCI-2E1 > C34 = C34 plus pCI-AS-2E1.

The finding that at least another cytochrome P450-overexpressing HepG2 cell line (CYP3A4-expressing cells) showed no induction of GCS-HS mRNA provides evidence for some specificity in the CYP2E1 induction of GCS-HS gene transcription in E47 cells and confirms the importance of the CYP2E1 isoform in mediating oxidative stress and toxicity. These results suggest the possibility that induction of CYP2E1 by ethanol and the resulting increased production of ROS may play a role in the induction of GCS when ethanol is administered in the intragastric infusion model (32). Experiments are in progress to evaluate the effect of in vivo induction of CYP2E1 on GCS expression and activity. Are the levels of CYP2E1 expressed in E47 cells of biological relevance? There is considerable variability in the content of CYP2E1 in human liver microsomes, e.g. oxidation of dimethylnitrosamine, a preferential substrate for CYP2E1, by several preparations of human liver ranged from 0.28 to 0.98 nmol/min/mg of microsomal protein (46). Parkinson (47) reported a CYP2E1 content of 22 pmol/mg of human microsomal protein; the content of CYP2E1 in E47 cells is ~50 pmol/mg of microsomal protein. The rate of oxidation of p-nitrophenol by E47 cell microsomes is ~0.3-0.4 nmol/min/mg of protein, which is within the range of p-nitrophenol oxidation by human liver microsomes (0.4-1 nmol/min/mg of protein). Thus, the level of CYP2E1 in E47 cells is within the physiological range for this P450 in human liver. Induction of GCS may have additional consequences beyond alcohol metabolism/effects and oxidative stress. Drugs such acetaminophen can be metabolized by several P450 isoforms, especially CYP2E1, to the reactive N-acetyl-p-benzoquinoneimine, which displays little toxicity when GSH is available for conjugation and detoxification (48-54). Lowering of GSH levels promotes acetaminophen toxicity by preventing quenching of the N-acetyl-p-benzoquinoneimine. Acetaminophen is highly toxic after chronic alcohol treatment, probably a reflection of induction of CYP2E1 (and other P450 isoforms), and is especially toxic when GSH is depleted. Indeed, in a previous study with HepG2 E9 cells, which contain lower levels of CYP2E1 than E47 cells, acetaminophen produced a concentration- and time-dependent loss of cell viability only when GSH levels were lowered by treatment with BSO (55). Studies are currently in progress to assess acetaminophen toxicity in E47 cells, which display higher levels of CYP2E1, but also higher levels of GSH; the former should promote toxicity of acetaminophen, whereas the latter should, at least initially, be protective. Treatment with BSO would be expected to strikingly elevate acetaminophen toxicity in E47 cells.

In summary, CYP2E1 overexpression in HepG2 cells up-regulates the levels of reduced GSH, which may serve as an adaptive mechanism to attenuate the CYP2E1-derived oxidative stress. Transfection with catalase or addition of GSH-EE decreases the CYP2E1-mediated induction of GCS-HS, suggesting that this induction may be H2O2-mediated. There appears to be some selectivity in the response of the HepG2 cells to CYP2E1, as cells expressing CYP3A4 do not show altered levels of GCS-HS mRNA. These results further emphasize the critical role of GSH in protecting against CYP2E1-mediated oxidative stress and toxicity.

    ACKNOWLEDGEMENTS

We thank Dr. Albert Morales for helpful discussion and suggestions and Dr. Natalia Nieto for guidance on some of the techniques used.

    FOOTNOTES

* This work was supported by United States Public Health Service Grants AA03312 and AA06610 from the National Institute on Alcohol Abuse and Alcoholism.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, One Gustave L. Levy Place, P. O. Box 1020, Mount Sinai School of Medicine, New York, NY 10029. Tel.: 212-241-7285; Fax: 212-996-7214; E-mail: Arthur.Cederbaum@mssm.edu.

Published, JBC Papers in Press, March 13, 2000, DOI 10.1074/jbc.M907022199

2 D. E. Feierman, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: GST, glutathione S-transferase; GCS, gamma -glutamylcysteine synthetase; GCS-HS, gamma -glutamylcysteine synthetase heavy subunit; GCS-LS, gamma -glutamylcysteine synthetase light subunit; ROS, reactive oxygen species; BSO, buthionine sulfoximine; DCFDA, 2',7'-dichlorofluorescein diacetate; DCF, 2',7'-dichlorofluorescein; PBS, phosphate-buffered saline; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; X-gal, 5-bromo-4-chloro-3-indolyl beta -D-galactopyranoside; GSH-EE, glutathione ethyl ester; ARE-4, antioxidant response element-4.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. DeLeve, L., and Kaplowitz, N. (1991) Pharmacol. Ther. 52, 287-305
2. Kaplowitz, N., Aw, T. Y., and Ookhtens, M. (1985) Annu. Rev. Pharmacol. Toxicol. 25, 714-744
3. Pickett, C. B., and Lu, A. Y. (1994) Annu. Rev. Biol. 11, 586-592
4. Borroz, K. I., Buetler, T. M., and Eaton, D. L. (1994) Toxicol. Appl. Pharmacol. 126, 150-155
5. Sekhar, K. R., Meredith, M. J., Kerr, L. B., Soltaninassab, S. R., Spitz, D. R., Xu, Z. Q., and Freeman, M. L. (1997) Biochem. Biophys. Res. Commun. 234, 588-593
6. Tian, L., Shi, M. M., and Forman, H. J. (1997) Arch. Biochem. Biophys. 342, 126-133
7. Mulcahy, R. T., Wartman, M. A., Bailey, H. H., and Gipp, J. J. (1997) J. Biol. Chem. 272, 7445-7454
8. Woods, J. S., and Ellis, M. E. (1995) Biochem. Pharmacol. 50, 1719-1724
9. Morales, A., García-Ruiz, C., Miranda, M., Marí, M., Colell, A., Ardite, E., and Fernández-Checa, J. C. (1997) J. Biol. Chem. 272, 30371-30379
10. Kuo, P. C., Abe, K. Y., and Schroeder, R. A. (1996) Am. J. Physiol. 271, C851-C862
11. Seelig, G. F., Simondsen, R. P., and Meister, A. (1984) J. Biol. Chem. 259, 9345-9347
12. Morales, A., Miranda, M., Sánchez-Reyes, A., Colell, A., Biete, A., and Fernández-Checa, J. C. (1998) FEBS Lett. 427, 15-20
13. Liu, R. M., Gao, L., Choi, J., and Forman, H. J. (1998) Am. J. Physiol. 275, L861-L869
14. Galloway, D. C., Blake, D. G., Shepherd, A. G., and McLellan, L. I. (1997) Biochem. J. 328, 99-104
15. Lieber, C. S. (1997) Physiol. Rev. 77, 517-544
16. Koop, D. R. (1992) FASEB J. 6, 724-730
17. Gorsky, L. D., Koop, D. R., and Coon, M. J. (1984) J. Biol. Chem. 259, 6812-6817
18. Ekstrom, G., and Ingelman-Sundberg, M. (1989) Biochem. Pharmacol. 38, 1313-1318
19. Dai, Y., Rashba-Step, J., and Cederbaum, A. I. (1993) Biochemistry 32, 6928-6937
20. Chen, Q., and Cederbaum, A. I. (1998) Mol. Pharmacol. 53, 638-648
21. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275
22. Tietze, F. (1969) Anal. Biochem. 27, 502-522
23. Griffith, O. W. (1980) Anal. Biochem. 106, 207-212
24. Fernández-Checa, J. C., and Kaplowitz, N. (1990) Anal. Biochem. 190, 212-219
25. Sze, G., Kaplowitz, N., Ookhtens, M., and Lu, S. C. (1993) Am. J. Physiol. 265, G1128-G1134
26. Flohé, L., and Günzler, W. A. (1984) Methods Enzymol. 105, 114-121
27. Habig, W. H., Pabst, M. J., and Jackoby, W. B. (1984) J. Biol. Chem. 249, 7130-7139
28. Carlberg, I., and Mannervick, B. (1985) Methods Enzymol. 113, 484-490
29. Paoletti, F., and Mocali, A. (1990) Methods Enzymol. 186, 209-221
30. Gipp, J. J., Bailey, H. H., and Mulcahy, R. T. (1995) Biochem. Biophys. Res. Commun. 206, 584-589
31. Levy, E. J., Anderson, M. E., and Meister, A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 9171-9175
32. Lu, S. C., Huang, Z. Z., Yang, J. M., and Tsukamoto, H. (1999) Hepatology 30, 209-214
33. Fernández-Checa, J. C., García-Ruiz, C., Oothkens, M., and Kaplowitz, N. (1991) J. Clin. Invest. 87, 397-405
34. Shaw, S., Rubin, K. P., and Lieber, C. S. (1983) Dig. Dis. Sci. 28, 585-589
35. Morton, S., and Mitchell, M. C. (1985) Biochem. Pharmacol. 34, 1559-1563
36. Kawase, T., Kato, S., and Lieber, C. S. (1989) Hepatology 10, 815-821
37. García-Ruiz, C., Morales, A., Ballesta, A., Rodés, J., Kaplowitz, N., and Fernández-Checa, J. C. (1994) J. Clin. Invest. 94, 193-201
38. Fahey, R. C., and Sundquist, A. R. (1991) Adv. Enzymol. Relat. Areas Mol. Biol. 64, 1-53
39. Rahman, I., Bel, A., Mulier, B., Lawson, M. F., Harrison, D. J., MacNee, W., and Smith, C. A. (1996) Biochem. Biophys. Res. Commun. 229, 832-837
40. Castro, V. M., Soderstrom, M., Carlberg, I., Widerstren, M., Platz, A., and Mannervick, B. (1990) Carcinogenesis (Lond.) 11, 1569-1576
41. Zhao, T., Singhai, S. S., Piper, J. T., Cheng, J., Pandya, U., Clark-Wronski, J., Awasthi, S., and Awasthi, Y. (1999) Arch. Biochem. Biophys. 367, 216-229
42. Kinter, M., and Roberts, R. J. (1996) Free Radical Biol. Med. 21, 457-462
43. Gipp, J. J., Chang, C., and Mulcahy, R. T. (1992) Biochem. Biophys. Res. Commun. 185, 29-35
44. Sakurai, K., and Cederbaum, A. I. (1998) Mol. Pharmacol. 54, 1024-1035
45. Chen, Q., Galleano, M., and Cederbaum, A. I. (1997) J. Biol. Chem. 272, 14532-14541
46. Yamazaki, H., Yun, C. H., Guengerich, F. P., and Shimada, T. (1992) Carcinogenesis (Lond.) 13, 1789-1794
47. Parkinson, A. (1996) Toxicol. Pathol. 24, 45-57
48. Holme, J. A., Dahlin, D. C., Nelson, S. D., and Dybing, E. (1984) Biochem. Pharmacol. 33, 401-406
49. Moore, M., Thor, H., Moore, G., Nelson, S. D., Moldeus, P., and Orrenius, S. (1985) J. Biol. Chem. 260, 13035-13040
50. Black, M. (1984) Annu. Rev. Med. 35, 577-593
51. Hinson, J. A. (1980) Rev. Biochem. Toxicol. 2, 103-130
52. Patten, C. J., Thomas, P. E., Guy, R. L., Lee, M., Gonzalez, F. J., Guengerich, F. F., and Yang, C. S. (1993) Chem. Res. Toxicol. 6, 511-518
53. Raucy, J. L., Lasker, J. L., Lieber, C. S., and Black, M. (1989) Arch. Biochem. Biophys. 271, 270-283
54. Anundi, L., Lahteenmaki, T., Rundgren, M., Moldeus, P., and Lindros, K. O. (1993) Biochem. Pharmacol. 45, 1251-1259
55. Dai, Y., and Cederbaum, A. I. (1995) J. Pharmacol. Exp. Ther. 273, 1497-1505

Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
N. J. Hodges, R. M. Green, J. K. Chipman, and M. Graham
Induction of DNA strand breaks and oxidative stress in HeLa cells by ethanol is dependent on CYP2E1 expression
Mutagenesis, May 1, 2007; 22(3): 189 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. M. Bailey, G. Robinson, A. Pinner, L. Chamlee, E. Ulasova, M. Pompilius, G. P. Page, D. Chhieng, N. Jhala, A. Landar, et al.
S-adenosylmethionine prevents chronic alcohol-induced mitochondrial dysfunction in the rat liver
Am J Physiol Gastrointest Liver Physiol, November 1, 2006; 291(5): G857 - G867.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Dey and A. I. Cederbaum
Geldanamycin, an Inhibitor of Hsp90, Potentiates Cytochrome P4502E1-Mediated Toxicity in HepG2 Cells
J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1391 - 1399.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Gong and A. I. Cederbaum
Transcription Factor Nrf2 Protects HepG2 Cells against CYP2E1 plus Arachidonic Acid-dependent Toxicity
J. Biol. Chem., May 26, 2006; 281(21): 14573 - 14579.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
D. Wu and A. I. Cederbaum
Opposite action of S-adenosyl methionine and its metabolites on CYP2E1-mediated toxicity in pyrazole-induced rat hepatocytes and HepG2 E47 cells
Am J Physiol Gastrointest Liver Physiol, April 1, 2006; 290(4): G674 - G684.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
D. Wu and A. Cederbaum
Glutathione Depletion in CYP2E1-Expressing Liver Cells Induces Toxicity Due to the Activation of p38 Mitogen-Activated Protein Kinase and Reduction of Nuclear Factor-{kappa}B DNA Binding Activity
Mol. Pharmacol., September 1, 2004; 66(3): 749 - 760.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
P. Gong, A. I. Cederbaum, and N. Nieto
The Liver-Selective Nitric Oxide Donor O2-Vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO) Protects HepG2 Cells against Cytochrome P450 2E1-Dependent Toxicity
Mol. Pharmacol., January 1, 2004; 65(1): 130 - 138.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. A. Caro and A. I. Cederbaum
Role of Phospholipase A2 Activation and Calcium in CYP2E1-dependent Toxicity in HepG2 Cells
J. Biol. Chem., September 5, 2003; 278(36): 33866 - 33877.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Gong, A. I. Cederbaum, and N. Nieto
Increased Expression of Cytochrome P450 2E1 Induces Heme Oxygenase-1 through ERK MAPK Pathway
J. Biol. Chem., August 8, 2003; 278(32): 29693 - 29700.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Mari, J. Bai, and A. I. Cederbaum
Adenovirus-Mediated Overexpression of Catalase in the Cytosolic or Mitochondrial Compartment Protects against Toxicity Caused by Glutathione Depletion in HepG2 Cells Expressing CYP2E1
J. Pharmacol. Exp. Ther., April 1, 2002; 301(1): 111 - 118.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. B. Sewer, V. Q. Nguyen, C.-J. Huang, P. W. Tucker, N. Kagawa, and M. R. Waterman
Transcriptional Activation of Human CYP17 in H295R Adrenocortical Cells Depends on Complex Formation among p54nrb/NonO, Protein-Associated Splicing Factor, and SF-1, a Complex That Also Participates in Repression of Transcription
Endocrinology, April 1, 2002; 143(4): 1280 - 1290.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
H. Jaeschke, G. J. Gores, A. I. Cederbaum, J. A. Hinson, D. Pessayre, and J. J. Lemasters
Mechanisms of Hepatotoxicity
Toxicol. Sci., February 1, 2002; 65(2): 166 - 176.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. M. MATO, F. J. CORRALES, S. C. LU, and M. A. AVILA
S-Adenosylmethionine: a control switch that regulates liver function
FASEB J, January 1, 2002; 16(1): 15 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Gastrointest. Liver Physiol.Home page
G. Robertson, I. Leclercq, and G. C. Farrell
Nonalcoholic Steatosis and Steatohepatitis: II. Cytochrome P-450 enzymes and oxidative stress
Am J Physiol Gastrointest Liver Physiol, November 1, 2001; 281(5): G1135 - G1139.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
A. A. Caro and A. I. Cederbaum
Synergistic Toxicity of Iron and Arachidonic Acid in HepG2 Cells Overexpressing CYP2E1
Mol. Pharmacol., October 1, 2001; 60(4): 742 - 752.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
275/20/15563    most recent
M907022199v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marí, M.
Right arrow Articles by Cederbaum, A. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marí, M.
Right arrow Articles by Cederbaum, A. I.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement